Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Public ClinicalTrials.gov record NCT03113500. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, etoposide, and prednisone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and combination chemotherapy may work better in treating patients with CD30-positive peripheral T-cell lymphoma.
Study identification
- NCT ID
- NCT03113500
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 48 participants
Conditions and interventions
Conditions
- Adult T-Cell Leukemia/Lymphoma
- Anaplastic Large Cell Lymphoma, ALK-Negative
- Anaplastic Large Cell Lymphoma, ALK-Positive
- Angioimmunoblastic T-Cell Lymphoma
- Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma
- Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma
- Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma
- Enteropathy-Associated T-Cell Lymphoma
- Hepatosplenic T-Cell Lymphoma
- Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
- Brentuximab Vedotin Drug
- Cyclophosphamide Drug
- Doxorubicin Drug
- Doxorubicin Hydrochloride Drug
- Etoposide Drug
- Etoposide Phosphate Drug
- Laboratory Biomarker Analysis Other
- Prednisone Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 25, 2017 (Actual)
- Primary completion
- Jul 16, 2021 (Actual)
- Completion
- Apr 25, 2027 (Estimated)
- Last update posted
- Aug 21, 2026
2017 – 2027
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03113500, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03113500 live on ClinicalTrials.gov.